The objective of this umbrella review is to summarize the results of meta-analyses on the use of SGLT-2 inhibitors in the treatment of heart failure patients and to offer a comprehensive evaluation of the efficacy and safety of these drugs in this population. This evidence concerns the gene SLC5A2 and heart failure.